Cargando…

Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease

Autoimmune factor V deficiency (AiFVD) is a rare bleeding disorder caused by factor V inhibitors. In this report, we present the case of an 89-year-old man who developed bleeding tendency during surgery to create arteriovenous fistula for hemodialysis. The bleeding tendency developed with prolongati...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuren, Eisuke, Kohagura, Kentaro, Kinjyo, Takanori, Zamami, Ryo, Nakamura, Takuto, Oshiro, Nanako, Sunagawa, Yoshitsugu, Omine, Kumiko, Kudo, Yuki, Shinzato, Yuki, Osaki, Tsukasa, Souri, Masayoshi, Ichinose, Akitada, Yamazato, Masanobu, Ishida, Akio, Ohya, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361254/
https://www.ncbi.nlm.nih.gov/pubmed/35943699
http://dx.doi.org/10.1007/s13730-022-00725-y
Descripción
Sumario:Autoimmune factor V deficiency (AiFVD) is a rare bleeding disorder caused by factor V inhibitors. In this report, we present the case of an 89-year-old man who developed bleeding tendency during surgery to create arteriovenous fistula for hemodialysis. The bleeding tendency developed with prolongation of activated partial thromboplastin and prothrombin time, following drug-induced eruption and eosinophilia. Significant reduction in coagulation factor activity and inhibitory pattern in cross-mixing tests suggested the presence of inhibitors to coagulation factors. Subsequently, we detected a factor V inhibitor and anti-factor V autoantibodies was confirmed using enzyme-linked immunosorbent assay with purified human plasma factor V. Thus, the patient was ‘definitely diagnosed’ with AiFVD in accordance with the diagnostic criteria enacted by the Japanese Ministry of Health, Labor, and Welfare. The bleeding tendency improved after initiating oral prednisolone 50 mg (1 mg/kg) followed by normalization of activated partial thromboplastin time and prothrombin time at the 34th day. After improving the coagulation system prolongation, the inhibitor and autoantibodies has been eradicated. Since it is suggested that drug-induced immune response can cause AiFVD, AiFVD should be considered in patients who undergo hemodialysis and develop failure of hemostasis and drug-induced eruption.